Venetoclax plus epcoritamab for relapsed or refractory CLL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase study tests whether combining venetoclax (a tablet) with epcoritamab (a targeted antibody) can control CLL/SLL that has come back or did not respond. It may help by boosting the immune system’s ability to attack the cancer while keeping the treatment schedule in cycles.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have CLL or, in part of the study, SLL that has come back or is resistant after at least one standard first treatment
- Your CLL/SLL is considered “needing treatment” based on established guideline criteria
- You are at least 18 years old and can handle study visits (typically good enough daily function)
- If you previously took venetoclax, you must be at least 24 months past the last dose and the cancer must not have grown during venetoclax treatment
- Your blood counts, kidney function, and liver tests must meet minimum safety levels (with limited exceptions if the CLL itself causes the low values)
- You must have certain infection and medication safety clearances (not active significant infections; hepatitis B/C checks; no prohibited interacting medicines)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether repeating two targeted medicines—venetoclax plus acalabrutinib—for a limited time can control CLL or SLL after you had a partial response to earlier venetoclax-based treatment. It may help people who need retreatment but want another approach beyond the first limited course.
This trial tests the drug epcoritamab as a consolidation therapy for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have had a partial response to a second-generation BTK inhibitor (with or without obinutuzumab) but still have detectable disease. The goal is to see if adding this treatment can lead to a deeper response and better outcomes.
This study tests a combination of three medications (epcoritamab, venetoclax, and ibrutinib) for people with untreated chronic lymphocytic leukemia (CLL) that has a TP53 alteration. The goal is to see if this triplet therapy is safe and effective for this specific type of CLL.
This trial tests a new combination of three drugs for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had treatment yet. The goal is to see if this approach helps control the disease with fewer side effects.
This trial tests how well venetoclax (a targeted pill for CLL) works in people whose CLL has come back or hasn’t responded. It also closely tracks early changes in the CLL cells to better understand what happens during treatment.
This Phase 2 trial tests a combination of three medicines to treat chronic lymphocytic leukemia (CLL) that has not been treated before and where the goal is to achieve very low remaining disease. It may help some people stay in remission longer, but eligibility depends on your age, organ function, and prior treatments.
Hear when a new CLL/SLL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.